As Sarepta fights for Duchenne therapy, another group of patients feels left behind
Sarepta Therapeutics is fighting to salvage its Duchenne therapy Elevidys amid safety setbacks. But families of children with another condition, limb-girdle muscular dystrophy, say they’ve been abandoned by the company, which recently scrapped nearly a decade of work on gene therapies for the disease. The decision has devastated parents, many of whom uprooted their lives […]
As Sarepta fights for Duchenne therapy, another group of patients feels left behind Read More »
